Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyMario Boccadoro(University of Turin), Jamie Cavenagh(St Bartholomew's Hospital)Cancer Cell InternationalJune 1, 200510.1186/1475-2867-5-18Cited by 230SaveCiteExport RISWatch citationsRelated PapersAspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial|Journal of Clinical Oncology|2011|321